Sentynl Therapeutics receives marketing authorization for Nulibry from UK MHRA
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ II, India
The drug will target specific genetic mutations prevalent in certain types of cancers
Chlorpromazine Hydrochloride Injection is used to treat certain mental/mood disorders
ANVISA issues CGMP to Concord Biotech’s Unit I
Leishmaniasis is caused by protozoan parasites which are transmitted by the bite of infected female phlebotomine sandflies
Isosorbide mononitrate is used to prevent chest pain (angina) in patients with a certain heart condition (coronary artery disease)
Subscribe To Our Newsletter & Stay Updated